Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Lexagene Holdings Inc LXXGQ

Lexagene Holdings Inc. is a molecular diagnostics company engaged in researching, developing and commercializing automated genetic analyzer devices in clinical and life science industries. The Company is focused on developing molecular diagnostic systems for pathogen detection and genetic testing for other molecular markers for on-site rapid testing in veterinary diagnostics, and for use in open-access markets such as food and water safety, clinical research, agricultural testing and biodefense. The Company's MiQLab System is an automated, open-access molecular diagnostic system for pathogen detection, allowing users to test for multiple pathogens onsite, returning results in approximately 2 hours. Its MiQLab System is an automated, multiplexing polymerase chain reaction (PCR)-based system designed for syndromic testing in human clinical diagnostics and veterinary diagnostics, as well as food safety testing, and open-access custom testing markets.


GREY:LXXGQ - Post by User

Post by TanzaniteMotherLodeon Jun 14, 2021 9:10am
127 Views
Post# 33380769

Tuesday June 15th

Tuesday June 15thOn Tuesday, June 15, Dr. Jack Regan will present as part of the ‘Microfluidic Hotseat’ at the Annual Microfluids Consortium. The consortium is hosted by the Centre for Business Innovation, a collaboration managing a portfolio around specific areas of business process and technology where members share information to pursue like-minded business and innovation goals. The title of Dr. Regan’s talk is Sample-to-Answer Pathogen Detection using Flow-Through Sample Preparation and Customized Multiplex PCR. Members will have the opportunity to meet microfluidics-enabled startups, such as LexaGene, whose pathogen detection system offers rapid molecular testing at the point of need, in multiple market verticals. Registration is still available for those wanting to watch the presentation.
<< Previous
Bullboard Posts
Next >>